Teva Pharmaceutical Inds LTD (TEVA) Holder Brahman Capital Trimmed Position; Weik Investment Services Raised Its Stake in Facebook Cl A (FB) by $1.56 Million as Share Price Declined

Facebook, Inc. (NASDAQ:FB) Logo

Brahman Capital Corp decreased its stake in Teva Pharmaceutical Inds Ltd (TEVA) by 30.9% based on its latest 2018Q3 regulatory filing with the SEC. Brahman Capital Corp sold 3.27M shares as the company’s stock declined 12.44% with the market. The hedge fund held 7.32M shares of the major pharmaceuticals company at the end of 2018Q3, valued at $157.73 million, down from 10.60 million at the end of the previous reported quarter. Brahman Capital Corp who had been investing in Teva Pharmaceutical Inds Ltd for a number of months, seems to be less bullish one the $19.26 billion market cap company. The stock decreased 7.53% or $1.44 during the last trading session, reaching $17.68. About 46.40 million shares traded or 345.85% up from the average. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has risen 22.93% since February 13, 2018 and is uptrending. It has outperformed by 22.93% the S&P500. Some Historical TEVA News: 26/03/2018 – Teva Announces the Launch of a Generic Version of Lialda® in the United States; 19/04/2018 – TEVA PHARMACEUTICAL-CONFIRMS CO, P&G INTEND TO DISSOLVE PGT HEALTHCARE PARTNERSHIP, SET UP TO MARKET COMPANIES’ OVER-THE-COUNTER MEDICINES, LATER THIS YEAR; 30/03/2018 – Teva’s Copaxone Sales Rise; Multiple Sclerosis Market Unchanged; 26/03/2018 – VANDA PHARMACEUTICALS – ON MARCH 23, GOT PARAGRAPH IV CERTIFICATION NOTICE LETTER REGARDING ANDA BY TEVA FOR GENERIC VERSION OF 20MG HETLIOZ CAPSULE; 03/05/2018 – TEVA EXPECTS TO SEE MORE COPAXONE COMPETITION LATER THIS YEAR; 10/05/2018 – TEVA CANADA ANNOUNCES THE LAUNCH OF TEVA-CYCLOSPORINE® OPHTHALMIC EMULSION, THE FIRST GENERIC VERSION OF RESTASIS® IN CANADA FOR THE TREATMENT OF DRY EYE DISEASE; 15/03/2018 – CORCEPT THERAPEUTICS INC – FILED A LAWSUIT AGAINST TEVA FOR “INFRINGEMENT OF CORCEPT PATENTS” COVERING USE OF KORLYM(MIFEPRISTONE) 300 MG TABLETS; 28/03/2018 – Xenon Pharmaceuticals Confirms Closing of Transaction with Teva and Announces Preferred Share Exchange Agreement with BVF Partn; 23/05/2018 – Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay; 28/03/2018 – NJ WARN NOTICE SAYS 101 JOBS AT TEVA’S ELIZABETH PLANT AFFECTED

Weik Investment Services Inc increased its stake in Facebook Inc. Cl A (FB) by 300.47% based on its latest 2018Q3 regulatory filing with the SEC. Weik Investment Services Inc bought 9,510 shares as the company’s stock declined 13.60% with the market. The institutional investor held 12,675 shares of the technology company at the end of 2018Q3, valued at $2.08M, up from 3,165 at the end of the previous reported quarter. Weik Investment Services Inc who had been investing in Facebook Inc. Cl A for a number of months, seems to be bullish on the $471.45 billion market cap company. The stock increased 0.09% or $0.15 during the last trading session, reaching $165.19. About 9.40 million shares traded. Facebook, Inc. (NASDAQ:FB) has declined 21.26% since February 13, 2018 and is downtrending. It has underperformed by 21.26% the S&P500. Some Historical FB News: 11/04/2018 – Facebook is facing questions following reports that research firm Cambridge Analytica improperly gained access to the personal data of as many as 87 million Facebook users; 24/04/2018 – Salesforce announces $2.2 bln French investment as Macron meets Trump; 20/03/2018 – FACEBOOK EXTENDS PRE-MKT LOSS TO 2.3% ON REPORT OF FTC PROBE; 10/04/2018 – ZUCKERBERG COMMENTS IN FACEBOOK POST AHEAD OF SENATE HEARING; 08/05/2018 – Facebook Names Jeff Zients to Board; 21/03/2018 – Germany summons Facebook over user data safety concerns -report; 13/04/2018 – The Takeaway: Facebook in 2020: ‘The AI Made Us Do It’; 18/04/2018 – Facebook could inadvertently benefit from new European privacy rules; 04/04/2018 – WKOW 27: #BREAKING: House committee announces Facebook CEO Mark Zuckerberg to testify before panel on April 11. (AP); 11/05/2018 – Facebook is reportedly ‘very serious’ about launching its own cryptocurrency

Weik Investment Services Inc, which manages about $228.44 million and $208.47M US Long portfolio, decreased its stake in Microsoft Corp. (NASDAQ:MSFT) by 4,190 shares to 98,665 shares, valued at $11.28M in 2018Q3, according to the filing. It also reduced its holding in Berkshire Hathaway B (BRKB) by 2,720 shares in the quarter, leaving it with 62,556 shares, and cut its stake in Tjx Companies (NYSE:TJX).

More notable recent Facebook, Inc. (NASDAQ:FB) news were published by: Marketwatch.com which released: “The Nasdaq is on pace to end its longest period from a bear-market low to an exit in nearly 30 years – MarketWatch” on February 13, 2019, also Seekingalpha.com with their article: “Facebook extends post-earnings gain to 12% – Seeking Alpha” published on January 31, 2019, Nasdaq.com published: “Big Afternoon for Q4 Earnings: FB, MSFT, TSLA, QCOM & V – Nasdaq” on January 30, 2019. More interesting news about Facebook, Inc. (NASDAQ:FB) were released by: Nasdaq.com and their article: “Implied Volatility Surging for Facebook (FB) Stock Options – Nasdaq” published on January 29, 2019 as well as Nasdaq.com‘s news article titled: “3 Reasons Why the Eero Buyout Will Lift Amazon Stock – Nasdaq” with publication date: February 12, 2019.

Among 57 analysts covering Facebook (NASDAQ:FB), 48 have Buy rating, 2 Sell and 7 Hold. Therefore 84% are positive. Facebook had 315 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Thursday, January 4 with “Buy”. The stock of Facebook, Inc. (NASDAQ:FB) earned “Buy” rating by Tigress Financial on Monday, April 30. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Tuesday, January 2 by Canaccord Genuity. The firm has “Buy” rating by Wedbush given on Monday, November 6. The stock of Facebook, Inc. (NASDAQ:FB) earned “Buy” rating by Robert W. Baird on Tuesday, October 17. Jefferies maintained the stock with “Buy” rating in Thursday, November 2 report. Citigroup maintained Facebook, Inc. (NASDAQ:FB) on Wednesday, October 31 with “Buy” rating. Canaccord Genuity maintained it with “Buy” rating and $230.0 target in Wednesday, January 31 report. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, October 31 report. The stock of Facebook, Inc. (NASDAQ:FB) earned “Hold” rating by BMO Capital Markets on Monday, October 16.

Investors sentiment increased to 1.13 in Q3 2018. Its up 0.04, from 1.09 in 2018Q2. It improved, as 123 investors sold FB shares while 598 reduced holdings. 154 funds opened positions while 661 raised stakes. 1.61 billion shares or 3.39% less from 1.66 billion shares in 2018Q2 were reported. 5,058 were reported by Wagner Bowman Mngmt. 10 has invested 0.08% of its portfolio in Facebook, Inc. (NASDAQ:FB). Vontobel Asset Mngmt Inc accumulated 1.37% or 1.07 million shares. Bailard Inc has invested 1.93% in Facebook, Inc. (NASDAQ:FB). Acadian Asset Ltd Llc has 57,990 shares for 0.04% of their portfolio. 190,000 were accumulated by Investmentaktiengesellschaft Fuer Langfristige Investoren Tgv. Miracle Mile Advsr Ltd Liability Company owns 73,914 shares or 1.1% of their US portfolio. Tradewinds Cap Mngmt Limited Liability Corporation invested in 0.34% or 5,372 shares. Citadel Advsr Limited Liability Com stated it has 0.32% of its portfolio in Facebook, Inc. (NASDAQ:FB). Horan Cap accumulated 157,315 shares. Two Sigma has invested 0.02% in Facebook, Inc. (NASDAQ:FB). Adage Capital Partners Gru Lc holds 3.00M shares. Chicago Equity Prns Limited Liability Corp has invested 0.75% in Facebook, Inc. (NASDAQ:FB). Azimuth Cap Ltd Llc stated it has 76,099 shares or 0.84% of all its holdings. 129,341 are held by Roosevelt Gru Inc Inc.

Since August 14, 2018, it had 0 insider buys, and 48 sales for $417.02 million activity. Another trade for 602,000 shares valued at $106.35 million was made by Zuckerberg Mark on Monday, August 27. Cox Christopher K had sold 5,300 shares worth $795,000 on Wednesday, January 30. 4,761 shares were sold by Wehner David M., worth $671,777 on Thursday, November 15. Shares for $7.79M were sold by Sandberg Sheryl on Tuesday, January 8. $509,438 worth of stock was sold by FISCHER DAVID B. on Monday, October 1. The insider Taylor Susan J.S. sold $294,835.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Seekingalpha.com which released: “Teva settles cinacalcet patent dispute with Amgen; shares up 3% premarket – Seeking Alpha” on January 03, 2019, also 247Wallst.com with their article: “What Held Back Teva in Q4 – 24/7 Wall St.” published on February 13, 2019, Seekingalpha.com published: “Stocks To Watch: Those Ticking Clocks – Seeking Alpha” on February 09, 2019. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Seekingalpha.com and their article: “Teva continues selloff, down 5% – Seeking Alpha” published on September 26, 2018 as well as 247Wallst.com‘s news article titled: “Short Interest Spikes in a Couple Major Pharma Stocks – 24/7 Wall St.” with publication date: January 28, 2019.

Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 4 Sell and 22 Hold. Therefore 26% are positive. Teva Pharma had 172 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Neutral” rating by Cantor Fitzgerald on Friday, June 16. Piper Jaffray maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Tuesday, January 30 with “Hold” rating. The rating was upgraded by Mizuho to “Buy” on Tuesday, January 9. JMP Securities maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Wednesday, September 6 with “Underperform” rating. The firm has “Buy” rating given on Monday, June 25 by Goldman Sachs. The stock has “Equal-Weight” rating by Barclays Capital on Monday, August 6. Cantor Fitzgerald maintained the stock with “Neutral” rating in Monday, July 16 report. Credit Suisse downgraded the shares of TEVA in report on Friday, August 4 to “Neutral” rating. The firm has “Underperform” rating given on Monday, November 6 by Credit Suisse. The rating was maintained by Wells Fargo with “Sell” on Thursday, May 3.

Facebook, Inc. (NASDAQ:FB) Institutional Positions Chart